Cardiovascular DiseasesNCT00005124
National Heart, Lung, and Blood Institute Twin Study
An observational study of Cardiovascular Diseases and Heart Diseases, run by National Heart, Lung, and Blood Institute (NHLBI).
Trial summary
To assess genetic effects on the variation of cardiovascular and pulmonary risk factors in a cohort of 514 pairs of white male veteran twins. Read more about this study
- Who is it for?
- Ages Up to 100 years, men only
- Conditions the study is for
- Cardiovascular Diseases, Heart Diseases, Lung Diseases
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- Jul 1969to Nov 1998
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 100 years
- Men only
- No healthy volunteers
- Child, Adult, Older adult
No eligibility criteria
About this study
To assess genetic effects on the variation of cardiovascular and pulmonary risk factors in a cohort of 514 pairs of white male veteran twins.
Read the detailed description
BACKGROUND:
In 1966, the National Academy of Sciences-National Research Council (NAS-NRC) began the development of a twin registry. Through state birth records, a group of twins born in 1917-1927 was ascertained and matched to veteran records to obtain a roster of 16,000 twins where both members of the pair were in military service. Veterans formed the basis of the registry because Veterans Administration files provided access to current addresses as well as potential for mortality follow-up. From this roster, a group of twins living within 200 miles of the examining centers and agreeing to cooperate was examined. This procedure yielded a set of 514 pairs of twins where both members of the pair were examined. At the time of initial examination, the World War II veteran twins were 42-56 years old. Since the initial examination, the twins have been followed by the NAS-NRC to maintain current addresses and mortality information.
The World War II veteran cohort was originally examined during the 1969-1973 period at five examination centers located in Framingham, Massachusetts; Davis, San Francisco, Los Angeles, California; and Indianapolis, Indiana. The objective of the initial examination was to estimate the heritability of cardiovascular risk factors. Results of the first examination showed significant heritability for height, weight, relative weight, systolic and diastolic blood pressure, glucose tolerance, uric acid, hematocrit, plasma triglycerides, and forced expiratory volume but not for total plasma cholesterol or any of the lipoprotein cholesterol fractions
.A second exam of the cohort was completed during 1981-1982. Of the original cohort of 1028 subjects, 792 or 77 percent were reexamined and approximately 5.5% had died. The objective of the second examination was to assess the change in cardiovascular risk factors over the ten year interval, assess the disease experience of the cohort and gather additional data on new cardiovascular risk factors as well as pulmonary function measurements and covariates. Examination two differed from examination one in that there was greater opportunity to standardize data collection for methods, laboratories, equipment, and time of examination. Greater emphasis was placed on pulmonary function testing. One objective of examination two that was not achieved was the determination of a sufficient number of cardiovascular events to do analyses of concordance of disease and analyses of disease occurrence in relation to risk factors. Analysis of data on 167 monozygotic pairs of twins and 176 dizygotic pairs of twins showed results similar to those of the first examination for systolic and diastolic blood pressure but, unlike the first examination, also showed significant genetic variance for total cholesterol and LDL cholesterol. HDL cholesterol continued to show no genetic variance.
The third examination of the original cohort was conducted in 1986-1987. The primary objective of the third examination was to assess the incidence of cardiovascular and pulmonary diseases for analyses relative to risk factor data and determine if the heritability of cardiovascular disease exceeded what was expected based on the known cardiovascular risk factors. Extensive pulmonary function testing was part of examination three as it was for examination two and provided longitudinal data for analyses of change in pulmonary function in relation to genetic and environmental factors. The exercise electrocardiogram was expanded to the entire cohort for examination three to provide additional data on sub-clinical disease.
DESIGN NARRATIVE:
The study was longitudinal in design and consisted of three examinations of the cohort over a period of eighteen years. Data collected in examination one in 1969-1973 included: a twin history questionnaire; personal, family and medical histories; a diet history; a physical examination; numerical data on anthropometry, hematology, and pulmonary function; supplemental lab data; an X-ray; clinical diagnostic impression; electrocardiogram; and blood analysis-fasting lipids. Data collected in examination two in 1981-1982 included: a personal and family history; deceased twin information; residence and occupational history; Thurstone Activity Scale; leisure time physical activity; social support; medical history; physical examination; clinical diagnostic impression; job mobility and stress; retirement information; Jenkins Activity Survey; blood lipid measurements. Data collected in examination three in 1986-1987 included the same data as collected in examination two plus an assessment of the prevalence for all twins and the incidence for a subgroup of twins of preclinical cardiovascular disease detected through noninvasive techniques.
The follow-up exam in 1986-87 collected baseline data on cognitive performance in 622 individuals, including 132 monozygotic and 134 dizygotic twin pairs. Beginning in December, 1994, a research grant was used to conduct a fourth exam in the surviving subjects of this cohort that used this rich resource of available data to determine the relationship between cardiovascular risk factors collected over 23 years of follow-up, changes in cognitive function since the last exam, and brain morphology assessed by magnetic resonance imaging (MRI). Given the mean age of this cohort (72 years) in 1995, the next several years represented a critical time to monitor age related changes in brain morphology and cognition. The addition of a fourth exam made the NHLBI Twin Study the longest longitudinal study of cardiovascular disease epidemiology in twin subjects (23 to 25 years of follow-up) and the first to investigate the contribution of genes and the environment to associations between CVD risk factors, cognitive performance, and brain morphology. There were five specific objectives of this study. The first was to evaluate the prospective and cross-sectional relationships of cardiovascular risk factors collected over 23 years of follow-up (e.g., blood pressure, lipids, obesity, smoking) and indices of brain morphology assessed at the fourth exam. The second objective was to determine the extent that twins discordant for essential hypertension or non-insulin-dependent diabetes mellitus (NIDDM) or cardiovascular disease (CHD) showed different MRI profiles. The third was to characterize the neuropsychological changes in performance from Exam 3 to Exam 4 and determine the contribution of genes and the environment to stability or change. The fourth objective was to use the data from exams 1 to 3 to investigate prospective relationships between CVD risk factors and decline in cognitive performance from Exam 3 to Exam 4. The fifth was to determine the heritability of the new measurements obtained for the first time at the fourth examination cycle (e.g., MRI measures of infarct area and localization, white matter hyperintensities (WMHI), and ventricular volumes).
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Lung Diseases, Hypertension, Diabetes Mellitus, Obesity
- Medical subject headings
- Cardiovascular Diseases, Heart Diseases, Lung Diseases, Hypertension, Diabetes Mellitus, Obesity, Coronary Disease, Myocardial Ischemia
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 May 2000 (estimated)
- Study startJul 1969
- Study completionNov 1998
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Cardiovascular DiseasesStudies of the same condition, open and under way.
- More trials run by National Heart, Lung, and Blood Institute (NHLBI)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
Sponsor and investigators
- Sponsor type
- US National Institutes of Health
- Investigators
- Nemat BorhaniDorit CarmelliMargaret ChesneyJoe ChristianGary FriedmanMarshall GreenbergClarence GrimmRay Rosenman
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00005124
- Sponsor's protocol ID
- 903
- Other IDs
- R01HL051429
- Status last verified
- May 2000
- First submitted
- 25 May 2000
- Last updated
- 16 Mar 2016
- Results posted
- No
Publications
Moore SS, Mukherji P, Leung M, Vrentas CE, Mwanja MM, Dai J. Methylation at CpG sites related to growth differentiation factor-15 was not prospectively associated with cardiovascular death in discordant monozygotic twins. Sci Rep. 2022 Mar 15;12(1):4410. doi: 10.1038/s41598-022-08369-9.
PubMed 35292700Dai J, Mukamal KJ, Krasnow RE, Swan GE, Reed T. Higher usual alcohol consumption was associated with a lower 41-y mortality risk from coronary artery disease in men independent of genetic and common environmental factors: the prospective NHLBI Twin Study. Am J Clin Nutr. 2015 Jul;102(1):31-9. doi: 10.3945/ajcn.114.106435. Epub 2015 May 6.
PubMed 25948664Krishnan E, Lessov-Schlaggar CN, Krasnow RE, Swan GE. Nature versus nurture in gout: a twin study. Am J Med. 2012 May;125(5):499-504. doi: 10.1016/j.amjmed.2011.11.010. Epub 2012 Feb 22.
PubMed 22365026
Study at a glance
From the registry record, last updated by the sponsor on 16 Mar 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- National Heart, Lung, and Blood Institute Twin Study
- ClinicalTrials.gov ID
- NCT00005124
- Acronym / sponsor ID
- 903
- Conditions
- Cardiovascular Diseases, Heart Diseases, Lung Diseases, Hypertension, Diabetes Mellitus, Obesity
- Study type
- Observational
- Recruitment status
- Completed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)US National Institutes of Health
- Study start
- Jul 1969
- Study completion
- Nov 1998 (actual)
- First posted
- 26 May 2000 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To assess genetic effects on the variation of cardiovascular and pulmonary risk factors in a cohort of 514 pairs of white male veteran twins.
Detailed description
BACKGROUND:
In 1966, the National Academy of Sciences-National Research Council (NAS-NRC) began the development of a twin registry. Through state birth records, a group of twins born in 1917-1927 was ascertained and matched to veteran records to obtain a roster of 16,000 twins where both members of the pair were in military service. Veterans formed the basis of the registry because Veterans Administration files provided access to current addresses as well as potential for mortality follow-up. From this roster, a group of twins living within 200 miles of the examining centers and agreeing to cooperate was examined. This procedure yielded a set of 514 pairs of twins where both members of the pair were examined. At the time of initial examination, the World War II veteran twins were 42-56 years old. Since the initial examination, the twins have been followed by the NAS-NRC to maintain current addresses and mortality information.
The World War II veteran cohort was originally examined during the 1969-1973 period at five examination centers located in Framingham, Massachusetts; Davis, San Francisco, Los Angeles, California; and Indianapolis, Indiana. The objective of the initial examination was to estimate the heritability of cardiovascular risk factors. Results of the first examination showed significant heritability for height, weight, relative weight, systolic and diastolic blood pressure, glucose tolerance, uric acid, hematocrit, plasma triglycerides, and forced expiratory volume but not for total plasma cholesterol or any of the lipoprotein cholesterol fractions
.A second exam of the cohort was completed during 1981-1982. Of the original cohort of 1028 subjects, 792 or 77 percent were reexamined and approximately 5.5% had died. The objective of the second examination was to assess the change in cardiovascular risk factors over the ten year interval, assess the disease experience of the cohort and gather additional data on new cardiovascular risk factors as well as pulmonary function measurements and covariates. Examination two differed from examination one in that there was greater opportunity to standardize data collection for methods, laboratories, equipment, and time of examination. Greater emphasis was placed on pulmonary function testing. One objective of examination two that was not achieved was the determination of a sufficient number of cardiovascular events to do analyses of concordance of disease and analyses of disease occurrence in relation to risk factors. Analysis of data on 167 monozygotic pairs of twins and 176 dizygotic pairs of twins showed results similar to those of the first examination for systolic and diastolic blood pressure but, unlike the first examination, also showed significant genetic variance for total cholesterol and LDL cholesterol. HDL cholesterol continued to show no genetic variance.
The third examination of the original cohort was conducted in 1986-1987. The primary objective of the third examination was to assess the incidence of cardiovascular and pulmonary diseases for analyses relative to risk factor data and determine if the heritability of cardiovascular disease exceeded what was expected based on the known cardiovascular risk factors. Extensive pulmonary function testing was part of examination three as it was for examination two and provided longitudinal data for analyses of change in pulmonary function in relation to genetic and environmental factors. The exercise electrocardiogram was expanded to the entire cohort for examination three to provide additional data on sub-clinical disease.
DESIGN NARRATIVE:
The study was longitudinal in design and consisted of three examinations of the cohort over a period of eighteen years. Data collected in examination one in 1969-1973 included: a twin history questionnaire; personal, family and medical histories; a diet history; a physical examination; numerical data on anthropometry, hematology, and pulmonary function; supplemental lab data; an X-ray; clinical diagnostic impression; electrocardiogram; and blood analysis-fasting lipids. Data collected in examination two in 1981-1982 included: a personal and family history; deceased twin information; residence and occupational history; Thurstone Activity Scale; leisure time physical activity; social support; medical history; physical examination; clinical diagnostic impression; job mobility and stress; retirement information; Jenkins Activity Survey; blood lipid measurements. Data collected in examination three in 1986-1987 included the same data as collected in examination two plus an assessment of the prevalence for all twins and the incidence for a subgroup of twins of preclinical cardiovascular disease detected through noninvasive techniques.
The follow-up exam in 1986-87 collected baseline data on cognitive performance in 622 individuals, including 132 monozygotic and 134 dizygotic twin pairs. Beginning in December, 1994, a research grant was used to conduct a fourth exam in the surviving subjects of this cohort that used this rich resource of available data to determine the relationship between cardiovascular risk factors collected over 23 years of follow-up, changes in cognitive function since the last exam, and brain morphology assessed by magnetic resonance imaging (MRI). Given the mean age of this cohort (72 years) in 1995, the next several years represented a critical time to monitor age related changes in brain morphology and cognition. The addition of a fourth exam made the NHLBI Twin Study the longest longitudinal study of cardiovascular disease epidemiology in twin subjects (23 to 25 years of follow-up) and the first to investigate the contribution of genes and the environment to associations between CVD risk factors, cognitive performance, and brain morphology. There were five specific objectives of this study. The first was to evaluate the prospective and cross-sectional relationships of cardiovascular risk factors collected over 23 years of follow-up (e.g., blood pressure, lipids, obesity, smoking) and indices of brain morphology assessed at the fourth exam. The second objective was to determine the extent that twins discordant for essential hypertension or non-insulin-dependent diabetes mellitus (NIDDM) or cardiovascular disease (CHD) showed different MRI profiles. The third was to characterize the neuropsychological changes in performance from Exam 3 to Exam 4 and determine the contribution of genes and the environment to stability or change. The fourth objective was to use the data from exams 1 to 3 to investigate prospective relationships between CVD risk factors and decline in cognitive performance from Exam 3 to Exam 4. The fifth was to determine the heritability of the new measurements obtained for the first time at the fourth examination cycle (e.g., MRI measures of infarct area and localization, white matter hyperintensities (WMHI), and ventricular volumes).
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
Study design
Who may qualify
- Ages
- Up to 100 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Mar 2016.
- Derived from this study: PubMed 35292700Moore SS, Mukherji P, Leung M, Vrentas CE, Mwanja MM, Dai J. Methylation at CpG sites related to growth differentiation factor-15 was not prospectively associated with cardiovascular death in discordant monozygotic twins. Sci Rep. 2022 Mar 15;12(1):4410. doi: 10.1038/s41598-022-08369-9.
- Derived from this study: PubMed 25948664Dai J, Mukamal KJ, Krasnow RE, Swan GE, Reed T. Higher usual alcohol consumption was associated with a lower 41-y mortality risk from coronary artery disease in men independent of genetic and common environmental factors: the prospective NHLBI Twin Study. Am J Clin Nutr. 2015 Jul;102(1):31-9. doi: 10.3945/ajcn.114.106435. Epub 2015 May 6.
- Derived from this study: PubMed 22365026Krishnan E, Lessov-Schlaggar CN, Krasnow RE, Swan GE. Nature versus nurture in gout: a twin study. Am J Med. 2012 May;125(5):499-504. doi: 10.1016/j.amjmed.2011.11.010. Epub 2012 Feb 22.
Related trials for Cardiovascular Diseases
Active, not recruitingPhase 3
ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Ischemic Optic Neuropathy
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nemat Borhani
Dorit Carmelli
Margaret Chesney
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiovascular Diseases and Heart Diseases, run by National Heart, Lung, and Blood Institute (NHLBI).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Mar 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00005124, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2016.